Salivary Gland Carcinoma — Trials

Salivary Gland Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 52
Recruiting: 25
Ph III recruiting: 0
Growth YoY: —
Industry share: 19%
Top sponsor: National Cancer Institute (NCI)
Termination share: 22.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (21)

clinicaltrialsPublishedShowing 1–13 of 13 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04140526	Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001)	active not recruiting	Phase 1 / Phase 2	733	OncoC4, Inc.INDUSTRY	2	Sep 14, 2026	clinicaltrials
NCT02978625	Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers	active not recruiting	Phase 2	68	National Cancer Institute (NCI)NIH	1